Print
Category: Editorials Editorials
Published: 13 October 2021 13 October 2021

Most of us have heard about Remdesivir and Regeneron, monoclonal antibodies, that are approved by CDC, WHO and FDA for the treatment of Covid-19.

Did you notice any three-letter agency that was left out? It's the National Institutes of Health, NIH.

If you are unfamiliar with the NIH, it is a part of the U.S. Department of Health and Human Services. NIH is the largest biomedical research agency in the world. You may read its mission and goals at this link:

https://www.nih.gov/about-nih/what-we-do/mission-goals

Notice the words "enhance health, lengthen life, and reduce illness and disability." Can you wonder if the federal government of the U.S.A is paying any attention to this mission?

Yes, I'm asking you to research things yourself. Do NOT take my word for it. But please keep reading.

You may have heard of the director, Francis S. Collins, M.D., Ph.D. He recently stepped down from his position.

This is the white-washed official version of why he stepped down:

https://www.nih.gov/news-events/news-releases/francis-s-collins-step-down-director-national-human-genome-research-institute

But just maybe because he was directly or indirectly involved in gain-of-function research, and this is pure speculation on this editor's part, although it is supported by the following link:

https://yated.com/nih-director-steps-down-amid-growing-scandal-about-covid-19-origins/

Keep reading, you will land on the whole point of this editorial.

Why would the federal government and the three-letter agencies that issue edicts choose Remdesivir and Regeneron as the approved drugs? Again, this is theory on many fronts: Maybe because they are expensive and it's always "Follow the Money?" You, the reader, if you are willing to do a bit of research and delving, can probably find out who in particular, other than the pharmaceutical companies are reaping the rewards of the expensive drugs. Maybe, just maybe people who have invested in those pharmaceutical companies or maybe because they have patents on "diseases" and pharmaceuticals? By the way, a disease cannot be patented, but that's a whole other conversation.

Remdesivir has numerous adverse events, including renal and liver toxicity (which means they can cause kidney or liver failure – two fairly major organs in our bodies). This writer is not making this up, it's in writing that was UPDATED by the NIH on July 8, 2021. [Editor's Note: It is recommended that you do a search, preferably NOT on Google, because it may not lead you to these controversial articles:
https://www.nih.gov/news-events/nih-research-matters/final-report-confirms-remdesivir-benefits-covid-19

https://pubmed.ncbi.nlm.nih.gov/33340409/

Note that at least one of the above articles says that Remdesivir should be used ONLY in a hospital setting. And then the WHO says otherwise in this article:

https://www.nbcnews.com/health/health-news/remdesivir-shouldn-t-be-used-hospitalized-covid-19-patients-who-n1248320

ADDED: A quote from https://www.charismanews.com/us/87046-clay-clark-s-reawaken-america-health-and-freedom-tour-is-making-a-difference-in-america-and-in-the-world?utm_source=Backorder&utm_medium=email&utm_campaign=Clay%20Clark%27s%20ReAwaken%20America%20Health%20and%20Freedom%20Tour%20Is%20Making%20a%20Difference%20in%20America%20and%20in%20the%20World%20%28W95EUq%29&_kx=eEeWFI8S1mRcUuW1pfV-qZyjPmsxojxxp9_APA4-6-VkZsVTsahPytHivMIvD1PQ.SwvL6p: "From the content (Attorney Tom) Renz presented, the audience learned that 25.9% of patients receiving Remdesivir died while hospitals paid between $2340.00 and $3100.00 for a single patient's course of treatment. This was compared to patients who were treated with Ivermectin, where 3.5% patients died with the cost for hospitals of $24.00 per patient. The question to be answers is: Why would hospitals spend thousands of dollars for a treatment with a high mortality rate, compared to another treatment that has an exceedingly low mortality rate for a much lesser cost? Could it be the fact the Centers for Medicare and Medicaid Services are bribing hospitals to select Remdesivir with a 20% bonus payout they receive by using specific codes to get the money?"

Regen-Cov is under emergency authorization and has not yet been studied well enough to know what adverse reactions can occur, although because the patient is treated with it through injection, it does cause the usual local pain and redness. Adverse reactions are usually specific to the patient.

Again, wondering why everyone is confused?

And finally we get to the point of this article. Note No. 1, in the following link and its adverse effects; then go to No. 2, which is banned by most hospitals in Canada and is very hard to come by in this country, except as a horse dewormer, but is available in Mexico, some have reported.

https://www.covid19treatmentguidelines.nih.gov/tables/table-2e/

Interestingly, No. 3 at the above link is also an anti-parisitic drug used to treat extreme diarrhea. This writer has not done extensive research on No. 3.

We come once more to Why? The only logical reason is because ivermectin is inexpensive and has been FDA approved for many years as an essential drug. But Remdesivir and Regeneron are expensive, and although they cause side effects, somebody somewhere is making boatloads of government taxpayer money on them.

Makes you kind of wonder what happened to the mission of enhancing health, lengthening life and reducing illness and disability.